Vir Biotechnology stock: Gilead deal brings up to USD 135 million upfront

Vir Biotechnology (ISIN US92764N1028) entered a collaboration with Gilead on October 14, 2026, covering three dual-masked T-cell engager candidates and up to USD 135 million in upfront and near-term payments, according to Business Wire. The agreement puts Vir's PRO-XTEN platform alongside Gilead's oncology development and commercialization capabilities.

Gilead deal broadens oncology work

Vir will handle discovery, design and optimization, while Gilead received an exclusive license to nominate and advance candidates through later development, manufacturing and commercialization. The payment structure includes USD 90 million in upfront consideration, comprising USD 65 million in cash and a USD 25 million equity investment, plus up to USD 45 million in near-term preclinical milestones.

The agreement also gives Vir potential access to as much as USD 1.74 billion in later development, regulatory and commercial milestones, together with tiered royalties on net sales. Those amounts are contingent on development and commercial progress, so the immediate financial effect is materially smaller than the long-term headline figure.

What could the deal mean for funding?

Vir reported USD 238.95 million of revenue and USD 80.08 million of net income for the second quarter ended June 30, 2026, compared with USD 1.21 million of revenue and a USD 110.96 million net loss in the year-earlier quarter, according to Markets Insider. The result was driven largely by collaboration-related payments, which makes the quarter an important balance-sheet event but not a recurring sales measure.

Three dated company milestones

On October 7, 2026, H.C. Wainwright raised its price target from USD 20.00 to USD 22.00 while keeping a Buy rating, as reported by Markets Insider. On October 14, 2026, Vir announced the Gilead collaboration and its three-candidate scope. On October 21, 2026, Vir announced its next quarterly results call, according to Vir Biotechnology.

Next reporting date

Vir will discuss its third-quarter results on November 4, 2026, at 4:30 p.m. ET, covering the quarter ended September 30, 2026. The date gives investors a defined checkpoint for cash, development spending and progress across the hepatitis delta and oncology programs.

Market value and investor context

Vir had a market capitalization of USD 1.8 billion on October 23, 2026, while its 52-week range was USD 4.82 to USD 12.00. The combination of a collaboration with conditional long-term payments, a profitable second quarter shaped by licensing income and an imminent reporting date leaves execution and cash conversion as the central measures for the next update.

Market context: Market report S&P 500.

More news and analyses on Vir Biotechnology stock